CJC-1295: a long-acting GHRH analogue

CJC-1295 is a synthetic growth-hormone-releasing hormone (GHRH) analogue engineered for one main purpose: to last far longer than natural GHRH. That extended duration is what makes it a distinct tool in growth-hormone-axis research.

The problem it was designed to solve

Natural GHRH has a very short life in circulation — it is degraded within minutes in laboratory models. CJC-1295 addresses this with structural modifications that resist enzymatic breakdown. Some versions include a technology, often referred to as DAC (a drug-affinity complex), that lets the molecule bind to blood proteins and extends its measurable presence considerably.

Why long action matters to researchers

A longer-acting GHRH analogue gives researchers a more stable, sustained signal to study rather than a brief pulse. In the published research literature this is used to examine how prolonged GHRH-receptor engagement affects the pituitary's release of growth hormone over time in study models. It is frequently investigated together with GHRP-class peptides to compare the two signalling routes.

Two families, often compared

CJC-1295 acts on the GHRH receptor. Peptides such as ipamorelin act on a separate receptor — the growth-hormone secretagogue receptor. Because the two families engage the axis through different doors, they are a recurring subject of comparative research. Our overview of growth hormone secretagogues sets out how GHRH analogues and GHRPs relate.

Form and quality

Like other research peptides, CJC-1295 ships as a lyophilised powder and is reconstituted with bacteriostatic water before use; our reconstitution and storage guide covers the standard method. Every batch is supplied with a certificate of analysis issued within six months of sale.